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Most tumors induced in experimental animals are immunologically rejected only
if the host has been previously immunized against the tumor (1) . Recently, however,
tumors have been induced by ultraviolet (UV) t light that are also rejected when
transplanted into normal syngeneic mice that have not been preimmunized (2) . These
tumors appear to be ideal for the study of naturally occurring host immunological
mechanisms that protect against the growth of malignant cells .
Previously we reported that resistance to UV-induced tumors depends on the
generation of tumor-specific lymphocytes (3) . Mice immunized against the tumor-
specific lymphocytes developed anti-idiotypic lymphocytes that selectively lysed tu-
mor-specific lymphocytes and such mice selectively lost the ability to reject a primary
tumor challenge . Furthermore, this loss of resistance correlated with the loss of the
capability of lymphocytes to respond to the tumor cells in vitro . Together, these
results demonstrated the importance of tumor-specific immunity in protecting against
malignant growth, and suggested that such immunity can be regulated by autogenous
anti-idiotypic immunity.
In the present study, we show that the capability of mice to reject a transplanted
UV-induced fibrosarcoma is lost progressively with age. One possible explanation for
this loss (4-7) is that older animals might develop an elevated level of anti-idiotypic
immunity (8), but this does not appear to be the case . Rather, aging mice appear to
lose the capacity to mount both idiotypic and anti-idiotypic responses involved in the
regulation of specific immunity to the tumor . This loss in turn is correlated with an
increasing degree of "nonspecific" or "cross-reactive" immunity that is ineffective in
controlling tumor growth .
Materials and Methods
Mice. Mammary tumor virus-negative (MTV-) C3H/HeN mice were obtained from a
colony of germ-free-derived, specific pathogen-free animals at the Frederick Cancer Research
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Center. The mice were 1.5-3 mo old when shipped and were used by age 2-6 mo unless
otherwise stated. The mice were kept at the La Rabida Institute in laminar flow hoods using
sterilized cages, food and water; under these conditions, the 50% survival for female animals
was >22 mo.
Fibrosarcoma Lines. The two fibrosarcomas, 1591 and 1316, were induced in C3H/HeN
(MTV-) mice by repeated exposure to UV light (9). The 1591 and 1316 fibrosarcoma lines
have non-cross-reacting tumor antigens (10). Both of these lines were adapted to culture from
the first transplant generation and both arestrongly immunogenic in that they regularlyregress
when transplanted into young syngeneic mice as tumor cell suspensions or tumor fragments,
afteran initial growth during thefirst 10 d. Thesetumors regularly grow progressively, however,
in nude mice or in syngeneic C3H mice that were immunosuppressed by either UV irradiation
or adult thymectomy and x-irradiation (9, 10). Both of these tumors kill the animals by
infiltrative growth and direct extension of the tumor into vital organs without macroscopic
evidence of distant metastases. So far, we have observed the development of a progressively
growing variant tumor in only one of >300 youngnormal animalsinjected with cloned cultured
cells or fragments from early transplant generations. All fibrosarcoma lines were cultured in
minimal essential medium (410-1100; Grand Island Biological Co., Grand Island, N. Y.)
containing 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin (600-5140;
Grand Island Biological Co.) (CMEM) .
Mixed Lymphocyte-Tumor Cell Cultures (MLTC).
￿
Culture medium was Dulbecco's modified
Eagle's medium (H-21; Grand Island Biological Co.) supplemented with 5% heat-inactivated
fetal bovine serum, 470 JLg L-glutamine/ml, 580 Ftg L-arginine/ml, 180 lag L-asparagine/ml, 60
Ftg folic acid/ml, 550 p,g sodium pyruvate/ml, 1% penicillin-streptomycin, and 5 X 10-5 M 2-
mercaptoethanol (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif)
added immediately before use. Spleens were aseptically removed, pressed througha wire screen,
and further dispersed with a Pasteur pipette. The cells were then washed three times with
culture medium, treated once with 0.83% (wt:vol) ammonium chloride to lyse erythrocytes,
and then washed once again with culture medium. Tumor cells were treated with 50 lag/ml
mitomycin C (Sigma Chemical Co., St. Louis, Mo.) for 45 min at 37°C and then washed four
times with culture medium. MLTC for the generation of tumor-specific cytolytic T cells were
made by adding 7 X 106 responder lymphocytes and 2 X 104 mitomycin C-treated stimulator
cells in 2.0 ml medium per culture (24-well tissue culture plate 3524; Costar, Data Packaging,
Cambridge, Mass.) . MLTC for the measurement of DNA synthesis of responding cells were
made by adding 106 responderlymphocytes and 2.9 X 103 mitomycin C-treated stimulator cells
in 200 p,l of medium perculture (96-well tissue culture plate 76-004-05; Linbro Chemical Co.,
Hamden, Conn.) . 1.0 [LCi [3H]TdR was added 12 h before harvest . Cells were harvested by
absorption onto glassfiber filter paperwith theuseofa cell harvester(OttoHiller Co., Madison,
Wis.).
Generation and Purification of Tumor-Specific Lymphoblasts and Induction cf Anti-Idiotypic
Immunity. The induction of anti-idiotypic immunity by immunization with syngeneic alloan-
tigen-specific T lymphoblasts has recently been described (11-14). We have slightly modified
this scheme fortheinduction ofanti-idiotypic immunity to tumor-specific lymphocytes, andwe
have previously described the general scheme for the generation, purification, and subsequent
immunization with tumor-specific lymphoblasts or nonresponding lymphocytes (3). Briefly,
mice were immunized with viable 1-mm3 fragments of the 1591 tumor implanted subcutane-
ously with a trocar into both inguinal regions. Spleen cells from tumor-immune animals were
removed aseptically 30 d after the primary immunization. Lymphocytes were restimulated in
an MLTC by adding 7.5 X 105 mitomycin C-treated 1591 tumor cells to 2.6 X 108 lymphocytes
in a 75-cm2 tissue culture flask (3705; Costar, Data Packaging) containing 75 ml of MLTC
medium. After 5 d in culture, tumor-reactive lymphoblasts were separated from nonresponding
lymphocytes (NRL) by equilibrium density centrifugation (15). Cells harvested from 5-d
cultures were washed three timeswith medium, and resuspended in a solution of bovine serum
albumin (fraction V; Armour Pharmaceutical Co., Chicago, Ill.), (p = 1.082), which was
overlaid with a less dense solution of bovine serum albumin (P = 1.060). Suspensions were spun
to equilibrium at 10,000 g for 20 min. The small dense NRL formed a pellet at the bottom of
the tube, whereas the less dense lymphoblasts floated at the interfaceof the two solutions. TheP . M . FLOOD, J. L . URBAN, M. L. KRIPKE, AND H . SCHREIBER
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purity of the separated fractions was routinely determined by three different criteria: size,
specific cytolytic activity, and [3H]TdR uptake . Gradient purified anti-1591 and anti-1316
lymphocytes showed at least 60-80% specific, lysis with <5% lysis of the control cell line using
a 50 :1 effector:target cell ratio . A suspension ofsuch purified tumor-specific T lymphoblasts or
NRL was mixed with equal parts Freund's complete adjuvant ; 0.2 ml ofthe mixture containing
10 7 cells was injected intraperitoneally . Two booster injections of cells in Freund's incomplete
adjuvant were given 3 and 6 wk later . 10 d after the final immunization, the immune reactivity
ofspleen cells from immunized mice was tested in vitro, or the spleen cells were used as a source
of anti-idiotypic cytolytic T cells .
Generation ofCytotoxic Lymphocytes In Vivo .
￿
Cytolytic peritoneal exudate cytotoxic lymphocytes
(PECL) were induced by a modification of a method previously described (16) . Mice were
injected once intraperitoneally with 1 X 10 7-2 X 107 mitomycin C-treated or untreated cultured
tumor cells in phosphate-buffered saline . At various times thereafter, the mice were killed by
cervical dislocation and their peritoneal cavities were rinsed with 5-10 ml ofCMEM containing
5 U/ml heparin to obtain PECL . The cells were washed with CMEM, and then incubated in
96-well tissue culture plates (Linbro Chemical Co.), 1 X 106-3 X 106 cells in 200111 CMEM per
well for 1 h at 37°C . Cells not adhering to plastic were washed and used as effectors for
chromium release assays .
Chromium Release Assay.
￿
Cytotoxicity assays for cell-mediated cytolysis of tumor cells, tumor-
specific lymphoblasts, or nonresponding lymphocytes were identical . 5 X 10 6-10 X 10 6 target
cells were labeled with 1001tCi 'Cr for 1 h at 37°C . 1001al of effector cells were placed in V-
bottomed 96-well microtiter plates (Cooke Engineering Co ., Alexandria, Va.), and mixed with
10° "Cr-labeled cells in 100 ltl CMEM. Unless stated otherwise, the effectontarget cell ratio
was always 50 :1 . Plates were spun at 800 g for 5 min. After 3-6 h o£ incubation, 100 ILI of
supernate was withdrawn . Spontaneous release was 10-15% of the maximum release of
radiolabel during the incubation period for the fibrosarcoma lines and <25% of the maximum
release for the purified lymphocytes . The percentage of specific lysis was calculated by the
formula :
experimental release - spontaneous release
specific lysis =
￿
X 100 .
total release - spontaneous release
In some experiments, effector cells were depleted of Lyt-2+ cells by incubation with a
monoclonal anti-Lyt-2 hybridoma antibody for 30 min at 4°C, followed by an incubation with
rabbit complement for 45 min at 37°C. A 1 :2 dilution of culture supernate from the anti-Lyt-
2 IgM hybridoma 2.155.2 (17) was used and was a generous gift from Dr . F . W. Fitch of The
University of Chicago. Control effectors were treated with medium instead of the anti-Lyt-2
supernate, followed by rabbit complement treatment . Rabbit complement used in these
experiments was serum from selected animals with low natural cytotoxicity to mouse myeloma
cells . This complement was subsequently absorbed with 80 mg of agar per ml of serum and
used at a final concentration of 1 :8 .
Results
Definition of the "Anti-Idiotypic Probe" and the "Common Anti-1591 Idiotype".
￿
We have
previously shown (3) that anti-1591 lymphoblast-immunized animals developed
cytolytic T cells that lysed lymphoblasts generated in culture from spleen cells of mice
immunized to 1591 . These cytolytic lymphocytes were called "anti-idiotypic" because
they selectively killed 1591-specific lymphocytes and recognized neither mitogen-
induced lymphoblasts nor lymphoblasts that were specific for other UV-induced
tumors having different antigens . Furthermore, these effector cells did not recognize
the lymphocytes obtained from animals that broke idiotype suppression after blast-
immunization .
In the present study, we test whether different animals immunized with 1591
regularly have lymphocytes that express an idiotype that is recognized by the anti-278
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idiotypic effector cells. Therefore, spleen cell suspensions from a large number of
tumor-immunized animals were individually cultured with stimulator tumor cells.
The lymphoblasts responding to the tumor cells in these cultures were used as 5tCr-
labeled target cells. Effector cells were spleen cells from animals that had been
immunized repeatedly with 1591-specific lymphoblasts as described in Materials and
Methods. Table I shows that 1591-specific lymphoblasts from different normal young
1591-immune animals were regularly sensitive to effector spleen cells from blast-
immune animals (average of 54% specific lysis), whereas control target cells consisting
of 1316-specific lymphoblasts were not affected. This indicated the regular presence
of shared antigenic determinants on 1591-specific lymphocytes of young immune
animals. Thus, the putative anti-idiotypic effector cells (anti-idiotypic probe) recog-
nize a common idiotype on 1591-specific T cells. Table I also shows that anti-idiotypic
cells generated on five different occasions showed comparable cytolytic activity. Thus
the variability in the amount of specific lysis of the 1591-specific lymphoblasts from
cultures of the different animals was small regardless of whether a single batch
TABLE I
Lymphocytes from 15 Mice Immunized with 1591 Share an Idioype
Recognized by Anti-Idiotypic Effector T Cells
* Effector cells were spleen cells from C3H mice immunized three times with
1591 tumor-specific lymphoblasts in adjuvant and tested 10 d to 3 mo after
the final lymphoblast immunization.
$ 1591-specific lymphoblasts were generated in a secondary MLTC from
individual animals immunized with 1591 fragments 1-3 mo earlier. Animals
1-6 were all tested in the same experiment. Animals 7-15 were tested on
different days.
§ Cells were tested in a 4-h 5'Cr release assay using as target cells purified 1591
tumor-specific lymphoblasts from experimental animals or 1316 tumor-spe-
cific lymphoblasts from 1316-immunized control animals at a 250:1 effector:
target cell ratio. Percent lysis was calculated as described in Materials and
Methods. The killing potential of the anti-idiotypic effector cells was com-
pletely eliminated by treatment with anti-Thy-1 .2 and complement . Fur-
thermore, the percent lysis of 1316 specific control target lymphocytes by the
anti-idiotypic effector cells was <2 in all experiments (data not shown).
Experiment
Mouse providing
anti-idiotypic lym-
phocytes*
Mouse providing
1591 tumor-spe-
cific lymphocytes$
Percent specific
lysis of 1591 tu-
mor-specific lym-
phocytes§
1 A 1 43
A 2 50
A 3 56
A 4 54
A 5 44
A 6 43
2 B 7 47
C 8 76
D 9 53
E 10 44
3 F 11 56
G 12 58
4 H 13 68
I 14 58
5 J 15 55P. M. FLOOD, J. L. URBAN, M. L. KRIPKE, AND H. SCHREIBER
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(experiment 1, 48% ± SD 6) or different batches of anti-idiotypic killer cells were used
(experiments 2-5, 57% ± SD 10) . This indicated that we can repeatedly generate an
anti-idiotypic probe that recognized a common anti-1591 idiotype .
Parameters for Induction ofAnti-Idiotypic Immunity.
￿
Normal 10-wk-old C3H mice were
immunized three times with 1591 tumor-specific lymphoblasts in adjuvant . Control
animals were immunized with NRL that had been isolated from the same MLTC
culture as the 1591-specific lymphoblasts . 10 d after the last immunization, spleen
cells from test and control mice were stimulated with 1591 or 1316 tumor cells . The
proliferative response was measured by [3H]TdR incorporation . Fig . 1 shows that
spleen cells from 1591 lymphoblast-immunized animals were unresponsive to 1591
tumor cells, whereas spleen cells from NRL-immunized animals responded normally
to stimulation with 1591 cells. Also, spleen cells from anti-1591 lymphoblast-immu-
nized animals were unable to generate cytolytic T cells specific for 1591 tumor cells,
even though they were able to generate a normal cytolytic T cell response to 1316
tumor cells when stimulated with these cells in a primary MLTC (Fig . 2) . Table II
shows that this specific unresponsiveness and cytolytic anti-idiotypic activity persisted
for at least 6 mo after the blast immunization .
We then investigated in repeated experiments the number of blasts required for the
generation of cytolytic anti-idiotypic activity and the induction of unresponsiveness .
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FIG. 1 .
￿
Specific suppression of the proliferative response to 1591 tumor cells by immunization with
syngeneic 1591 tumor-specific lymphoblasts. Responder spleen cells (7 X 105per well) from normal
animals (A), animalsimmunized with 1591 tumor-specific lymphoblasts (" ), or animalsimmunized
withNRL(O) were cultured with 2 X 10 3 mitomycin C-treated 1591 stimulator tumor cells . Results
were calculated by subtracting the background value of spleen cells alone from the value of total
incorporation ofspleen cells andtumor cells . Vertical bars indicate t 1 SD offour replicate cultures.280
FiG. 2.
￿
Lack of cytolytic response of spleen cells from lymphoblast-immunized animals to 1591
tumor cells. Spleen cells from lymphoblast-immunized, NRL-immunized, or normal animals were
incubated with 1591 or 1316 tumor cells and after 5 d ofculture tested at a 100:1 effector to target
cell ratio. N, stimulated with 1591, tested on 1591 sarcoma; 0, stimulated with 1591, tested on 1316
sarcoma; ®, stimulated with 1316, tested on 1591 sarcoma; and0, stimulated with 1316, tested on
1316 sarcoma.
TABLE II
Persistence ofSpecific Anti-Idiotypic Immunity and Concurrent Lack ofSpecific Immunity to 1591 Tumor
Cells
LOSS OF TUMOR- AND IDIOTYPE-SPECIFIC IMMUNITY WITH AGE
Blast-immunized NRL-immunized
￿
Normal
Percent specific lysis of§ Percent specific lysis ofJJ
* Mice were immunized with 107 purified lymphoblasts or 107 NRL injected intraperitoneally in Freund's
complete adjuvant. Animals were boosted twice at 3-wk intervals with the same number of lymphocytes
in incomplete adjuvant.
$ At different times after the immunizations, spleen cells from blast-immunized and control animals were
tested (a) for their capability to specifically lyse 1591 tumor-specific lymphoblasts of the dominant clones
and (b) for their capability to generate 1591 tumor-specific T cells in a primary 5-d MLTC culture.
Three animals per group were killed at 1 and 3 mo and two animals per group were killed at 6mo.
§Spleen cells were tested in a4-h 5'Cr release assay using as target-purified 1591-specific or 1316-specific
lymphoblasts at a 250:1 effector:target cell ratio. These lymphoblasts were obtained after standard in
vitro restimulation of 1591- or 1316-immune spleen cells andpurified by density gradient centrifugation .
The percentage of specific lysis was calculated as described in Materials and Methods.
~~ Effector cells generated in a 5-d MLTC by spleen cells from blast-immunized or control animals were
tested in a 3-h "Cr release assay using as target 1591 or 1316 tumor cells at a 50:1 effectontarget cell
ratio. Percent specific lysis was calculated as described in Materials and Methods.
Not tested.
Cells from from mice im-
d wch*
Time me after
immuniza-
tion$
mo
Age of
mouse at
analysis
mo
Anti-1591
lympho-
blasts
Anti-1316
lympho-
blasts
1591 tu-
mor cells
1316 tu-
morcells
Anti-1591 blasts 1 5 55±1 I±I I±0 3t2
NRL 1 5 1f0 1t1 48±16 1t1
Anti-1591 blasts 3 7 61 ±4 0±0 1 1 4±3
NRL 3 7 NTT NT 29 ± 7 3 t 2
Anti-1591 blasts 6 10 64 ±8 2±2 0 0 1±1
NRL 6 10 NT NT 27±7 3t2Table III shows that a dose of 10' lymphoblasts per injection generated significant
anti-idiotypic activity. Furthermore, this high dose was capable of totally abrogating
the response of the animals to 1591 tumor cells ; however, lymphocytes from animals
receiving half as many lymphoblasts responded specifically and almost as well as 1591
tumor cells in vitro, as did lymphocytes from control animals .
Effect of Age on the Development of Anti-Idiotypic Immunity .
￿
Animals of different age
groups were immunized repeatedly with 107 anti-1591 lymphoblasts or 107 NRL in
adjuvant . Table IV shows that as the animals increased in age, anti-idiotypic
immunity was less readily induced . Animals that had been immunized at the age of
3 mo showed the highest anti-idiotypic activity, and spleen cells from these mice were
unresponsive to 1591 tumor cells in vitro . Animals immunized at the age of 6 mo
showed a lower but nevertheless significant level of cytolytic anti-idiotypic activity .
Interestingly, cells from these animals respond specifically to 1591 tumor cells in vitro .
However, the anti-1591 lymphoblasts of these blast-immunized animals were insen-
sitive to the anti-idiotypic probe, indicating that idiotypically different 1591-specific
lymphocyte clones were involved in the response of the 11-13-mo-old animals .
TABLE III
A Threshold Number ofLymphoblasts is Required to Induce Anti-Idiotypic Immunity and Concurrent
Unresponsiveness to 1591 Tumor Cells
P . M . FLOOD, J . L . URBAN, M . L. KRIPKE, AND H . SCHREIBER
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28 1
Anti-idiotypic cytoly-
tic activity
(percent specific
Tumor-specific im-
mune response
(percent specific
* Mice were immunized with different doses of 1591-specific lymphoblasts or NRL intraperitoneally in
Freund's complete adjuvant . Animals were boosted twice at 3-wk intervals with the same number of
lymphocytes in incomplete adjuvant and tested 10 d to 3 mo thereafter .
$ Spleen cells from blast-immunized and control animals were tested for their capability to specifically lyse
1591 tumor-specific lymphoblasts of the dominant clonotype in a 4-h 5'Cr release assay using as targets
purified 1591-specific or 1316-specific lymphoblasts at a 250 :1 effectontarget cell ratio . These lympho-
blasts were obtained after standard in vitro restimulation of 1591- or 1316-immune spleen cells and
purified by density gradient centrifugation . The percentage of specific lysis was calculated as described
in Materials and Methods.
§ See footnote 11 to Table II .
Experi-
ment
Dose
Cells from mice
immunized with*
lysis)$
Anti-1591 Anti-1316
lympho- lympho-
blasts blasts
lysis)§
1591 tu- 1316 tu-
mor cells mor cells
1 1 X 107 1591-specific blasts 72 3 <0 <0
5 X 10 6 1591-specific blasts 8 <0 10 <0
1 X 106 1591-specific blasts 2 <0 14 <0
5 X 105 1591-specific blasts <0 <0 22 1
1 x 107 NRL 7 <0 21 1
2 1 x 107 1591-specific blasts 76 <0 1 l
5 x 106 1591-specific blasts <0 <0 25 <0
1 x 106 1591-specific blasts <0 <0 27 2
5 X 105 1591-specific blasts <0 <0 33 <0
1 X 107 NRL <0 <0 40 0
3 1 x 10 7 1591-specific blasts 44 2 <0 <0
5 x 106 1591-specific blasts 2 <0 24 0
1 X 106 1591-specific blasts 2 1 50 0
5 x 105 1591-specific blasts 1 1 48 1
1 x 10 7 NRL I 3 59 3282
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Effect of Age on the Induction of Cytolytic Anti-Idiotypic Activity and on the Induction of Unresponsiveness
to 1591 Tumor Cells
Exper-
iment
TABLE IV
Sensitivity
of tumor-
reactive
lympho-
blasts to
lsis y
-
pic
ell
* Mice of different ages were immunized with 107 purified lymphoblasts or 10 7 NRL intraperitoneally in
Freund's complete adjuvant . Animals were boosted twice at 3-wk intervals with the same number of
lymphocytes in incomplete adjuvant .
$ See footnote $ to Table 111 .
§ See footnote ~~ to Table II .
The tumor-reactive lymphocytes from blast-immunized and control animals were gradient-purified and
used as "'Cr-labeled target cells using anti-idiotypic killer cells obtained from a separate group of young
blast-immunized animals as effector cells at a 250 :1 effector:target cell ratio in a 4-h assay . The percentage
of specific lysis was calculated as described in Materials and Methods .
Animals that had been immunized at the age of 9 or 12 mo did not develop any
detectable anti-idiotypic activity. Furthermore, the responses of these blast-immunized
animals to the 1591 tumor cells in vitro showed high cross-reactivity to 1316 target
cells . Tumor-reactive lymphocytes from spleens of older NRL-immunized controls
also demonstrated a high degree of cross-reactivity ; however, there were marked
differences in the sensitivity of the tumor-reactive lymphocytes to the anti-idiotypic
probe for this group as compared with the blast-immunized group . Spleen cells from
blast-immunized animals of any age failed to develop tumor-reactive lymphocytes
expressing the common 1591-specific idiotype, whereas young NRL-immunized con-
trol animals developed tumor-reactive lymphocytes expressing the common anti-1591
idiotype . It can be seen in Table IV, however, that the tumor-reactive lymphocytes
zation
mo mo
1591
lym-
phob-
lasts
1316
lym-
phob-
lasts
1591
tumor
cells
1316
tumor
cells
yant
idiotypro
1 3 8 Anti-1591 blasts 53 <0 7 2 <0
6 11 Anti-1591 blasts 28 <0 16 3 <0
9 13 Anti-1591 blasts 2 <0 25 5 <0
12 17 Anti-1591 blasts <0 <0 32 44 <0
3 8 NRL <0 <0 19 1 54
6 11 NRL <0 <0 24 4 53
9 13 NRL <0 <0 31 17 26
12 17 NRL <0 <0 38 45 13
2 3 10 Anti-1591 blasts 71 1 <0 <0 <0
6 13 Anti-1591 blasts 37 1 18 7 <0
9 16 Anti-1591 blasts 9 5 26 65 3
12 19 Anti-1591 blasts 10 <0 25 60 <0
3 10 NRL 6 <0 21 1 24
6 13 NRL 2 <0 16 t0 7
9 16 NRL 0 1 23 56 5
12 19 NRL 6 <0 28 63 0
Anti-idiotypic cy- Tumor-specific
tolytic activity immune response
(percent specific (percent specific
Age at lysis)$ lysis)§
start of Age at Immunogen*
immuni- analysis Anti- Anti-generated by the NRL-immunized control animals demonstrated a progressive de-
crease in sensitivity to the anti-idiotypic probe with increasing age . This change was
paralleled by the increase in cross-reactivity of these tumor-reactive lymphocytes to
1316 tumor cells described above .
Effect of Age on the Generation of Tumor-specific Responses In Vitro.
￿
The above experi-
ments showed that aging animals did not generate significant anti-idiotypic immune
responses after blast immunization . Furthermore, older blast- and NRL-immunized
animals generated nonspecific 1591-reactive lymphocytes in culture that lacked the
exquisite specificity of cytolytic lymphocytes from young animals . We then wished to
determine whether such age-dependent change in the tumor reactivity pattern would
also be observed in normal untreated animals because it was possible that this age-
dependent pattern in the blast- and NRL-immunized animals was related to the
chronic nonspecific stimulation by intraperitoneal adjuvant present in these animals.
Therefore, we compared in three independent experiments young, middle-aged, and
older nonimmunized animals in terms of their capability to generate tumor-specific
lymphocytes in vitro. Spleen cells from animals of different ages were stimulated in a
primary MLTC with 1591 tumor cells . After 5 d the effector cells were tested on
either 1591 or 1316 tumor cell targets in a "'Cr release assay . The results from these
studies were similar and therefore pooled . Fig. 3 shows that as the age of the animals
increased, their reactivity to 1591 tumor cells remained constant . The cross-reactivity
of the effector cells, however, increased considerably between 10 and 13 mo of age . All
the cytolytic activity could be totally eliminated by pretreatment of the effector cells
with anti-Lyt-2 and complement (data not shown) . The tumor-reactive lymphocytes
40
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AGE OF MICE (months)
Ftc . 3 .
￿
Age-related loss of the specificity of tumor-reactive lymphocytes generated in a primary
MLTC ofspleen cells from normal animals of different ages . Spleen cells of normal mice ofdifferent
ages were stimulated with 1591 tumor cells in a 5-d MLTC . The culture-generated lymphocytes
were then tested in a 4-h "'Cr release assay using 1591 (" ) or 1316 (O) tumor cells as targets . The
percent lysis was calculated as described in Materials and Methods . Data from two independent
experiments are pooled. Vertical bars indicate t i SEM, two or three individual animals. The
effector to target cell ratio is 50 :1 .284
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generated by spleen cells from the same animals as those used in Fig . 3 were also
gradient purified and used as "'Cr-labeled target cells for cytolytic anti-idiotypic
effector cells or control effector cells . Fig. 4 shows that the participation ofthe common
1591 tumor-specific lymphocyte clone in an in vitro immune response to 1591 tumor
cells markedly declined with increasing age beginning at about 8 mo of age.
Effect of Age on Development of Tumor-specific Immunity.
￿
We had previously demon-
strated that the presence of tumor-specific lymphocyte clones was necessary for young
animals to resist the 1591 tumor (3) . Therefore, normal animals might be expected to
lose their natural resistance to the 1591 tumor cells during middle age . To test this
hypothesis we implanted 1-mm3 1591 tumor fragments subcutaneously into mice of
different ages and monitored the mice for progressive tumor growth during the
following 8 wk . TableV shows that, as anticipated, the tumor resistance of animals
challenged with 1591 decreased with increasing age .
We also studied the immune response of PECL of mice of different ages to 1591
tumor cells . Animals were injected intraperitoneally with 1591 tumor cells and the
responding PECL were removed 10 d later. Fig. 5 shows that cells from mice 2-6 mo
old showed strong cytolytic reactivity to 1591 tumor cells . PECL from middle-aged
animals (9-15 mo) showed considerably less reactivity to 1591 tumor cells and those
from 16-22-mo-old animals were completely nonresponsive .
Interestingly, the increased cross-reactivity to 1316 tumor cells with increasing age,
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￿
Age-dependent decrease in the participation of the dominant 1591 tumor-specific lympho-
cyte clone(s) in an in vitro response to 1591 tumor cells . Tumor-reactive lymphocytes from normal
animals (0) or NRL-immunized animals (fl) of different ages were generated in primary MLTC
cultures . The tumor-reactive lymphocytes were purified, labeled with "'Cr, and used as target cells
to test their sensitivity to anti-idiotypic effector cells specific for the dominant anti-1591 lymphocyte
clone(s) in a 4-h 5'Cr release assay at a 250 :1 effector to target cell ratio . Each symbol represents
analysis of an individual animal . The results of three independent experiments comparing the
different age groups are included. Control effector cells from NRL-immunized animals caused <5%
lysis of 1591-specific lymphoblasts, and 1316-specific control target lymphoblasts were lysed by the
three anti-idiotypic probes <5% (data not shown) .P . M . FLOOD, J . L . URBAN, M. L . KRIPKE, AND H . SCHREIBER
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TABLE V
Effect ofAge on the Resistance ofNormal Mice to Challenge with the 1591
Tumor
* Normal C3H mice of different age groups were implanted with two 1-mm3
fragments of the 1591 fibrosarcoma in both inguinal regions.
$ Number of mice that showed progressively growing tumors 8 wk after tumor
challenge.
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16-22
FIG. 5 .
￿
Effect of age on the generation ofPECL specific for 1591 tumor cells . Female mice of
different ages were injected intraperitoneally with 107 1591 tumor cells that had either been
mitomycin C-treated or left untreated . PECL were removed 8 d later and tested at an effector :
target cell ratio of 100 :1 . Percent lysis was calculated as described in text . (*), amount of specific
lysis by PECL from an individual 1591-immunized animal ; (O), amount ofspecific lysis by PECL
from nonimmunized controls . The resultsoftwo independent experiments weresimilarand therefore
pooled in this figure. Lyt-2 and complement treatment regularly reduced the reactivity of effector
cells to 1591 cells to < 10% lysis and untreated effectorcells caused< 10% lysis of 1316 cells (data not
shown) .
which we had observed in culture-generated tumor-reactive lymphocytes, was not
found for lymphocytes recovered from the peritoneal cavity of these animals . The
lysis of 1316 tumor cells by PECL was <5% at an effector:target cell ratio of 100:1 .
All the reactivity to 1591 tumor cells could be eliminated by anti-Lyt-2 antibody and
complement .
Age of mice at
time of challenge*
rno
Number of mice
challenged
Sex
Number of mice
with progressively
growing tumors$
2 20 Female 0
2 20 Male 0
6 20 Female 1
6 20 Male 2
10 20 Female 3
10 20 Male 7
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Discussion
In recent studies, we have shown that the expression of the 1591 tumor-specific
antigen on 1591 tumor cells (18) and the immune response of tumor-specific T cells
to this antigen (3) are critically important for resistance of normal animals to the
1591 tumor. In the present study, we found that progressing age caused qualitative as
well as quantitative changes in the immune response of the animals to the 1591
tumor-specific antigen. Apparently as a consequence of aging, animals became
progressively more susceptible to challenge with the 1591 tumor.
We have found that young mice regularly recognize the 1591 tumor antigen with
lymphocytes that share idiotypic determinants. This suggests the common expression
of a selected group of clonotypesor idiotypes on lymphocytes responding in the young
animal to the 1591 tumor. By 8-9 mo of age, however, the participation of these
lymphocytes expressing the common idiotype is reduced, although there are consid-
erable variations among individual animals in the extent of this reduction (Fig. 4) .
Nevertheless, the tumor-reactive lymphocytes at this age still show the same high
specificity for 1591 tumor cells as had been found in the younger animals (Fig. 3) .
Thus, aging animals begin to lose clonal dominance at this age in that they respond
with idiotypically different lymphocyte clones that are still specific for the 1591 tumor.
The age period during which animals respond with these idiotypically different but
tumor-specific clonotypes is apparently short because only slightly older animals (10-
13 mo) respond to tumor challenge with different tumor-reactive lymphocytes that
show marked cross-reactivity with 1316 tumor cells (Fig. 3 and Table IV).
Because this and the previous studies (3) indicate the host-protective value of the
dominant 1591-specific lymphocyte clones for the resistance of the host to the tumor,
it is important to determine how the dominance of these T cell clones is controlled.
Several independent studies in other systems have suggested that the relative partic-
ipation of B cell idiotypes in an immune response depends on naturally present anti-
idiotypic helper or suppressor T cells (19-22) . In some instances, the activity of
naturally present anti-idiotypic helper T cells seems to control the dominance of a
certain clonotype in an antibody response (19, 20) . In other instances, normal
individuals seem to have anti-idiotypic suppressor T cells that are responsible for
thelack of participation of certain B cell clonotypes in an immune response (21, 22).
Unfortunately, little is known about the various factors that may control dominance
ofT cell idiotypes in an immune response. We have previously shown that autogenous
anti-idiotypic immunity can regulate 1591 tumor-specific lymphocyte clones (3) .
Thus, age-dependent changes in the anti-idiotypic compartment may be at least
partially responsible for the age-dependent changes of clonal dominance in the 1591
system.
Anti-idiotypic helper cells may, for example, participate in the control of the
dominant 1591-specific clonotypes, and aging may cause a loss in the response of anti-
idiotypic helper T cells. This hypothesis is consistent with our finding that the ability
of animals to develop anti-idiotypic immunity declines with age. Our findings also
suggest that a spontaneous generation of suppressive anti-idiotypic T cells is probably
not responsible for the loss of clonal dominance. Certainly, we have not detected a
spontaneous development of anti-idiotypic killer cells in aging animals. Thus, the
mechanism for the changes we have observed in clonal dominance in aging miceP. M. FLOOD, J. L. URBAN, M. L. KRIPKE, AND H. SCHREIBER
￿
287
appears to be different from the one mediating the immune suppression in young
mice caused by immunization with 1591-specific lymphocytes of the common idiotype.
Immunization of young mice to produce anti-idiotypic immunity (which permits
tumor growth) may switch the young host from the production of anti-idiotypic
helper cells to the production of the observed anti-idiotypic killer cells. Such a
phenomenon may in fact be the reason for the threshold effects of the dose of
lymphocytes needed to induce effective idiotype-suppression as observed in this study
(Table III) and in a previous study in the alloantigen system (11).
We know of no published studies using carefully defined, idiotypically restricted
systems that report changes in T cell clonal dominance with increasing age. Recent
studies at this institution, however, indicate that the loss of B cell clonal dominance
and the development of minor, previously absent or suppressed B cell clones specific
for phosphorylcholine antigens occur not only after idiotype suppression (23) but also
as a result of aging of the animals (D. Kaplan and J. Quintans, unpublished results).
Thus, aging may have a parallel effect on B and T cell clonal dominance.
In contrast to the qualitative age-dependent changes mentioned above, there was
no change in the absolute quantitative level of cytolysis of 1591 tumor cells by
cultured lymphocytes from unprimed animals of different ages (Fig. 3) . This result is
in agreement with earlier investigations that also found no age-dependent change in
the cytotoxicity of short-term-cultured lymphocytes to syngeneic fibrosarcomas of
three different mouse strains, even when mice beyond their 50% survival mode were
used (24) . Although T cells generated from spleens of older animals can lyse 1591
tumor cells effectively in vitro, the value of these lymphocytes, if generated in vivo, in
protecting the host against a challenge of 1591 tumor cells must be relatively small,
because individuals lose their natural resistance to the 1591 tumor cells in spite of
generating such T cells.
We have no evidence to support the possibility that cytotoxic lymphocytes generated
in short-term culture are specific for a putative cross-reacting tumor antigen on UV
tumors, because such lymphocyte suspensions also kill non-UV-induced, nontrans-
formed, nonmalignant syngeneic fibroblast cell lines (unpublished results) . Possibly
the spleen cells of older animals have an increased tendency to generate self-reactive
rather than tumor-specific T cells in culture when stimulated with immunogenic
tumor cells, because it has recently been suggested that alloreactive T lymphocytes
from aged mice are cross-reactive and express increased lysis of autologous and third-
party target cells (25) . It is possible that the age-dependent increase in the generation
of such cross-reactive cells occurs preferentially in vitro, because we find it difficult to
retrieve such highly cross-reactive Lyt-2+ cells in vivo from the peritoneal cavities of
1591-immunized mice. Such cells may be generated in large numbers in vivo but we
may not be able to retrieve the majority of them from the peritoneal cavity due to
trapping by normal tissues of the host. In any case, because the total immune response
of an individual to the tumor antigen is not found to increase with increasing age, an
increased participation of nonspecific T cell clones must mean a decreased contribu-
tion by tumor-specific clones and therefore a decreased protection against tumor
growth.
The capability of normal mice or their cells in culture to mount a tumor-specific
immune response declines during middle age, i.e., between 9 and 14 mo. At this time,
individual mice begin to become susceptible to the tumor challenge. The high degree288
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of individual variation in the capability of different animals to mount a tumor-specific
immune response may explain why only some animals become susceptible to the
tumor challenge at this age. The decline in tumor-specific immune responses may
also reduce immune selection pressures against tumor variants that occur. In fact, the
unusually high immunogenicity of UV or methylcholanthrene-induced tumors in-
duced in UV-exposed mice has been attributed to the lack of immunoselection in
such mice because their immune system had been suppressed by the UV light (10,
26-28) . Because most of these tumors developed in 8-15-mo-old animals (9, 28), we
feel that the decreased immune potential of the animals at this age may have
contributed to the lack of immunoselection observed in these animals. In any event,
our results show that older animals, even in the absence of carcinogen-induced
immunosuppression, permit the growth of tumors that are regularly rejected by the
intact immune system of the young. If tumors developing in older individuals have
indeed retained tumor-specific antigens, we may be able to recover the response ofthe
tumor-specific lymphocytes in aging individuals, and thus induce strong resistance to
their developing tumors .
Summary
The ultraviolet light-induced fibrosarcoma 1591 undergoes "first-set rejection"
when transplanted into normal syngeneic mice. We found, however, that the primary
resistance of normal mice decreases with age, beginning at 9-12 mo, equivalent to
middle age for mice. Mice lose with age the capacity to mount both idiotypic and
anti-idiotypic responses responsible for controlling the growth of the tumor. This loss
was correlated with quantitative as well as qualitative changes in the response, such
as changes in specificity and clonotype. Normal young mice regularly expressed a
dominant common anti-1591 "idiotype" as defined by an anti-idiotypic probe. The
capability of normal mice to respond with lymphocytes of this dominant common
idiotype began to decline at about 8 mo of age. At this time, animals still generated
tumor-specific lymphocytes, but these lymphocytes appear to be idiotypically different
lymphocyte clones. With further increase in age, animals responded with tumor-
reactive lymphocytes that showed a marked cross-reactivity to other tumor target cell
lines. Both in vivo and in vitro, the capability of normal mice to mount an immune
response that was specific for the 1591 tumor cells decreased between 9 and 14 mo,
which was the age individual mice became increasingly susceptible to a challenge
with 1591 tumor cells. Thus, our data suggest that clones of tumor-specific T cells
provide primary and early protection of young animals against challenge with
malignant 1591 cells. However, the dominance of these tumor-specific T cell clones in
a primary immune response is lost in middle-age.
Because the ability of animals to mount anti-idiotypic immune responses also
declined in middle-aged animals, it is possible that the observed loss of clonal
dominance of tumor-specific clones with increasing age is at least partially related to
age-dependent changes in the anti-idiotypic compartment.
Receivedforpublication 16 March 1981.
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